Coherus BioSciences, Inc. (NASDAQ:CHRS - Get Free Report) passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $1.28 and traded as high as $1.53. Coherus BioSciences shares last traded at $1.50, with a volume of 1,921,419 shares trading hands.
Analyst Ratings Changes
A number of analysts have commented on the company. StockNews.com lowered Coherus BioSciences from a "buy" rating to a "hold" rating in a report on Saturday, October 19th. HC Wainwright reiterated a "buy" rating and set a $7.00 price target on shares of Coherus BioSciences in a report on Wednesday, December 4th. Finally, Robert W. Baird raised their price objective on Coherus BioSciences from $4.00 to $6.00 and gave the company an "outperform" rating in a research note on Thursday, December 5th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $5.38.
Check Out Our Latest Stock Report on CHRS
Coherus BioSciences Price Performance
The company has a market capitalization of $158.99 million, a P/E ratio of -17.25 and a beta of 0.86. The firm has a fifty day moving average price of $1.18 and a 200-day moving average price of $1.28.
Institutional Inflows and Outflows
Institutional investors have recently bought and sold shares of the business. Systematic Financial Management LP purchased a new stake in shares of Coherus BioSciences during the 3rd quarter worth approximately $28,000. TIAA Trust National Association purchased a new stake in Coherus BioSciences in the second quarter worth $47,000. Hsbc Holdings PLC increased its position in Coherus BioSciences by 10.6% in the second quarter. Hsbc Holdings PLC now owns 103,183 shares of the biotechnology company's stock worth $179,000 after buying an additional 9,905 shares during the last quarter. FMR LLC raised its stake in shares of Coherus BioSciences by 21.1% in the third quarter. FMR LLC now owns 225,113 shares of the biotechnology company's stock valued at $234,000 after buying an additional 39,204 shares during the period. Finally, Rhumbline Advisers lifted its position in shares of Coherus BioSciences by 19.5% during the 2nd quarter. Rhumbline Advisers now owns 154,904 shares of the biotechnology company's stock valued at $268,000 after buying an additional 25,241 shares during the last quarter. Institutional investors own 72.82% of the company's stock.
Coherus BioSciences Company Profile
(
Get Free Report)
Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.
Featured Articles
Before you consider Coherus BioSciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Coherus BioSciences wasn't on the list.
While Coherus BioSciences currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
